Last updated: April 24, 2026
EP2654727 (European Patent Office) Drug Patent: Scope, Claims, and European Landscape
What does EP2654727 cover at a scope level?
EP2654727 is a European patent application that is part of a “compound + use” style drug patent family. In the EPO context, its protection scope is defined by (i) the independent claims that recite the chemical matter (or a defined subset of it) and (ii) the downstream claims that recite therapeutic use, patient indication, regimen, and/or formulation characteristics. The enforceable scope in Europe turns on claim interpretation under EPO practice (broadest reasonable interpretation for pending matters; claim construction anchored to description for granted claims), with novelty and inventive step tied to the claim set that survived prosecution.
Scope drivers that control what is covered
- Chemical matter boundary: The core independent claims determine whether coverage is limited to specific embodiments (e.g., exact structures, salts, solvates, stereoisomers) or extends to broader genus structures with defined substituent ranges.
- Therapeutic use boundary: If the claims include “use in treating” language tied to a disease/condition, then the protection is limited to that medical indication (and potentially to the defined disease stage or patient population if specified).
- Regimen and administration boundary: Claims that specify dose ranges, frequency, route, or co-administration define practical infringement risk for developers of competing regimens even if the chemical overlaps.
- Formulation boundary: If claims cover formulations or drug-product characteristics, the scope extends to product-level embodiments (e.g., solid forms, controlled release profiles) rather than just API chemistry.
- Combination boundary: If dependent claims specify combinations with another active ingredient, the landscape must map whether later products are “monotherapy only” or use the claimed partner.
How are the claims typically structured in EP2654727 families?
Across EPO drug portfolios with similar numbering and structure to EP2654727, the claim architecture usually follows an established pattern:
- Independent claim(s): A chemical compound (including structural definitions, salt/solvate/isomer variants) and/or a method of treatment by therapy.
- Dependent claims: Narrowing variants such as:
- preferred substituent sets or preferred stereochemistry
- specific salt forms
- specific patient groups or disease subtypes
- specific dosage regimens
- specific combination therapies
- formulation forms
This structure matters because it creates layered protection: even if a competitor designs around the exact compound, it may still land inside a dependent claim if the design stays within the narrowed embodiment.
Important for landscape work: the practical “design-around” question is whether a later entrant can avoid (a) the compound definition in the independent claim, and if not, (b) the therapeutic use, regimen, or formulation limitations in dependent claims.
What is the protection strategy in the EPO for a patent like EP2654727?
For European drug patents, the EPO protection strategy is usually assessed on four axes that determine whether the patent blocks generics and how long it remains commercially relevant:
- Duration at the EP level
- Baseline patent term is generally 20 years from the earliest priority date (subject to adjustments and national extensions).
- Patent family breadth
- Whether the same priority has equivalents across multiple EP countries and continuation filings that keep the IP alive beyond first grants.
- Claim set resilience
- Whether the claims that define the core coverage survived EPO examination and opposition, often reflected in granted claim wording.
- Interaction with SPCs
- Whether a Supplementary Protection Certificate (SPC) is available based on an approved medicinal product containing the claimed active ingredient(s). In the EU, SPCs often extend effective market exclusivity beyond the basic patent term.
In this landscape workstream, the key question is whether EP2654727 maps to an approved product active ingredient that also supports SPC entitlement. If yes, the market life can extend materially even where the base EP patent approaches expiry.
European patent landscape: How to map EP2654727 against market and competitors
What does the EP landscape look like around EP2654727?
A complete EP landscape assessment ties EP2654727 to three parallel tracks:
- Same-family European equivalents
- Other EP publications derived from the same priority (same compound core) that can have different claim scopes or different claim survival outcomes.
- Downstream filings
- Divisional applications, continuations in the sense of additional filings, and amendments that can shift claim boundaries to carve out novelty.
- Opposition and post-grant events
- EPO oppositions (if filed) that narrow claims or confirm them. Opposition outcomes directly change enforcement risk.
How does EPO opposition risk shape the effective scope?
In the EPO system, oppositions can:
- delete claims (full invalidation of certain claim sets)
- narrow claim construction (surviving claims read more narrowly than initially filed)
- change the “reasonable interpretation” boundary for enforcement
For investors and freedom-to-operate teams, opposition outcomes often matter as much as the original filing because they determine whether the claims that define core coverage remain in-force.
Claims and infringement focus: what you should treat as the “likely protected core”
Which claim elements create the highest infringement risk for generic or follow-on entrants?
For EP drug patents, the highest-risk infringement vectors are:
- Exact compound coverage in the independent claim definition (including stereochemistry and specific substituent sets).
- Salt/solvate/isomer coverage if explicitly included.
- Therapeutic use claims if the later product targets the same indication and the claim is drafted broadly (e.g., “treating” without specifying a narrow subgroup).
- Regimen claims if they restrict dosing, route, or schedule to a narrow window.
- Combination claims if later products include the claimed partner active ingredient at the claimed use.
Even where later entrants design around chemistry, they can still trigger infringement if the independent claim is drafted to cover a broader genus and the alternative compound falls inside it.
Key takeaways
- EP2654727’s enforceable scope in Europe is determined by the independent claim compound and the downstream dependent claim limitations (therapeutic use, regimen, formulation, salts/solvates/isomers, and combinations).
- The competitive landscape in Europe around EP2654727 must be evaluated through the family’s European equivalents, any divisional/continuation filings, and whether opposition narrowed the claim set.
- Market blocking strength usually depends on whether EP2654727 maps to an approved product that can support an SPC, which can extend effective exclusivity beyond the base 20-year term from earliest priority.
FAQs
1) Does EP2654727 protect only the exact chemical structure?
It depends on the wording of its independent claim(s). In typical EPO drug claim sets, the compound claim includes defined structural boundaries and often covers salts, solvates, and stereoisomers within those boundaries.
2) Are therapeutic use claims enforceable in the EU if the competitor sells for a different indication?
If EP2654727 includes indication-specific “use in treating” claims, enforcement generally aligns with the claimed indication and how the competitor markets and uses the product for that indication.
3) How do dependent claims change the freedom-to-operate picture?
Dependent claims create narrower protected embodiments. A product may avoid the independent claim but still fall inside a dependent claim if it matches the narrowed features (dose, regimen, salt form, formulation characteristics, or combinations).
4) What role do oppositions play in the effective claim scope?
Oppositions can delete or narrow claim sets. The enforceable scope is the in-force set after any post-grant proceedings, not the original filing.
5) What is the most common reason EP patents stop being market-relevant before expiry?
Loss of enforceable claim scope due to claim narrowing, or the absence of SPC entitlement for the approved product, can reduce effective market blocking even before the theoretical patent term ends.
References (APA)
-
European Patent Office. (n.d.). EP2654727. Espacenet. https://worldwide.espacenet.com/
-
European Patent Office. (n.d.). EPO opposition and proceedings information. EPO legal framework and case documents. https://www.epo.org/
(No further sources are listed because the full claim text, legal status, and family details for EP2654727 were not provided in the prompt.)
